Medical Device | March 12, 2026
FDA nod to LifeVac De Novo, paving for next-generation anti-choking device
The FDA classified LifeVac as a Class II medical device
The FDA classified LifeVac as a Class II medical device
The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The approval comes after a systematic review of published literature
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
Giredestrant shows promise despite missing primary goal
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Subscribe To Our Newsletter & Stay Updated
